NICE approves life changing gene therapy for treating spinal muscular atrophy

8 March 2021 - A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular ...

Read more →

NICE rejects rare blood cancer treatment Poteligeo in final appraisal

4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...

Read more →

NICE backs NHS use of Lilly’s Olumiant in eczema

3 March 2021 - Eli Lilly’s Olumiant has received a UK NICE recommendation for the treatment of moderate-to-severe atopic dermatitis ...

Read more →

NHS prescription charges set to rise in England

2 March 2021 - The NHS prescription charge in England is set to increase to £9.35 from 1 April 2021 ...

Read more →

Thousands of breast cancer patients to have routine access to NICE-approved drug combination

26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...

Read more →

NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE

25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...

Read more →

NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria

25 February 2021 - NICE has today issued draft guidance for public consultation which recommends sapropterin (Kuvan, BioMarin) for treating phenylketonuria ...

Read more →

Tecartus recommended by NICE

24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...

Read more →

NICE terminates appraisal of Novartis medicine

24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal ...

Read more →

Lupin responds to NICE Appraisal Consultation Document on NaMuscla (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders

16 February 2021 - Lupin is disappointed that NICE has published an Appraisal Consultation Document recommending not to approve NaMuscla (mexiletine) ...

Read more →

bluebird bio ‘baffled’ after NICE rejects beta thalassaemia gene therapy

16 February 2021 - It’s back to the drawing board for bluebird bio and its discussions with NICE, which has ...

Read more →

NICE rejects Lilly’s Verzenios for advanced breast cancer

15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of ...

Read more →

bluebird bio’s beta thalassaemia gene therapy rejected by NICE

12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s ...

Read more →

Skin cancer drug recommended for routine NHS use

12 February 2021 - An appeal period has now opened until 26 February 2021. ...

Read more →

Does NICE influence the adoption and uptake of generics in the UK?

14 February 2021 - The aim of this paper is to examine generic competition in the UK, with a special focus ...

Read more →